The BIOMEDE trial was a clinically adaptive trial where DMG tumours from patients in Australia, Europe and the UK were specifically tested against three approved inhibitors targeting EGFR (erlotinib), mTOR (everolimus) or PDGFR (dastanib) for efficacy and in combination with standard radiotherapy followed by maintenance therapy (NCT02233049). This evidence concerns the gene EGFR and neoplasm.